Normal organ [Ga]DOTATOC uptake during PRRT: challenging the assumption of stable background shaped by cold somatostatin analogues treatment.

Date publication

novembre 2025

Journal

European journal of nuclear medicine and molecular imaging

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher , Pr MALOUF Gabriel , Pr IMPERIALE Alessio , Dr POROT Clémence , Dr BALTZINGER Philippe

Tous les auteurs :
Ait Talhiq H, Baltzinger P, Frega J, Collen C, Colin Valentin M, Malouf GG, Porot C, Abdelghani MB, Addeo P, Goichot B, Berti V, Imperiale A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41240092

Résumé

To characterize longitudinal changes in normal-organ [Ga]DOTATOC uptake through sequential PET/CT during [Lu]DOTATATE PRRT in patients with small intestine neuroendocrine tumors (SiNET) and to relate these changes to the somatostatin-analogue (SSA) regimen, early PET response after two PRRT cycles, and 1-year outcome.

Mots clés

Neuroendocrine, Normal organ, Peptide receptor radionuclide therapy, [177Lu]DOTATATE, [68Ga]DOTATOC

Référence

Eur J Nucl Med Mol Imaging. 2025 11 15;: